Abbott

By Dave Muoio 11:31 am January 16, 2020
Bigfoot Biomedical, a diabetes startup looking to automate insulin delivery via a connected insulin pen, has kicked off its Series C round with an initial tranche of $45 million. The raise is headed once again by Abbott, with prior backers Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management pitching in once again. Alongside the news of its raise, Bigfoot...
By Laura Lovett 04:18 pm October 14, 2019
This morning med tech giant Abbott announced a new deal with chronic care management company Omada Health that will integrate Abbott’s FreeStyle Libre continuous glucose monitor (CGM) with Omada's health coaching platform.  Going forward, eligible users with Type 2 diabetes will have the option to integrate data from their FreeStyle Libre, including glucose reading, trends and patterns, with...
By Dave Muoio 03:10 pm October 1, 2019
Sixth time's the charm? Roche’s Accu-Chek Connect Diabetes Management App has notched its sixth device recall from the FDA, this time due to meter-to-app data transfer issues for users with Android OS 8.0 and above. According to the agency’s posting, Roche notified partners, users and call centers of the issue and released and update addressing the problem before the end of that month. Prior to...
By Laura Lovett 02:54 pm September 19, 2019
Sanofi has been active in the digital space this week inking two big deals: one with tech company Abbott and the other with digital platform Happify.  The first partnership with Abbott will combine the medtech company’s FreeStyle Libre, a continuous glucose monitoring system, and the pharma giant’s insulin dosing information to create smart pens and insulin titration apps.  Sanofi is currently...
By Dave Muoio 03:23 pm July 17, 2019
Following a major sales bump in the second quarter of 2019, Abbott Laboratories is planning to significantly ramp up manufacturing for its FreeStyle Libre continuous glucose monitoring system, the company shared during an investor’s call this morning. Specifically, the company highlighted a 72.9% increase in organic sales growth during the three-month period, reaching a worldwide total sales...
By Dave Muoio 04:03 pm June 10, 2019
On Friday, the American Diabetes Association kicked off its annual conference in San Francisco, where academics, vendors and other stakeholders congregated to unveil new study results and major announcements related to diabetes management. And while MobiHealthNews already put together a roundup featuring an opening salvo of the show’s announcements, the past few days have seen a tidal wave of new...
By Jonah Comstock 02:41 pm June 7, 2019
Implantable CGM company Senseonics has received approval from the FDA for the non-adjunctive indication for its Eversense device. Senseonics is only the third company to secure this indication, which allows a CGM to be used for insulin dosing in lieu of a fingerstick glucometer, though patients will still need to use fingersticks twice a day for calibration. The company plans to go live with the...
Novo Nordisk insulin pens
By Jonah Comstock 11:04 am February 20, 2019
Novo Nordisk’s connected insulin pens will integrate with the Abbott Freestyle Libre system, allowing Freestyle Libre users to see data about their insulin alongside their glucose readings, the companies announced this morning. "Lack of reliable information is a cause of huge frustration for many people with diabetes and their doctors," Anders Dyhr Toft, CVP of commercial innovation at Novo...
By Jonah Comstock 05:44 am November 7, 2018
By and large, Q3 2018 was a slow and steady quarter for pharma moves in digital health, at least in terms of publicly disclosed operations. At events during the quarter, the likes of Johnson & Johnson, AstraZeneca, Novartis and Sanofi discussed digital therapeutics and expressed a healthy mixture of skepticism and enthusiasm for the space. “These technologies have a tremendous opportunity to...
By Jonah Comstock 09:34 am November 1, 2018
Just a short while after securing a CE Mark for its second generation device, Abbott has been granted FDA clearance for FreeStyle LibreLink, a companion mobile app for its 10 to 14-day CGM. The launch adds a long-awaited feature for US users that’s been available for some time in Europe: users will be able to scan their sensors with an app on their smartphone — and see their latest reading —...